Cue Biopharma, Inc. (CUE)

Market Cap	72.96M
Revenue (ttm)	5.49M
Net Income (ttm)	-50.73M
Shares Out	48.64M
EPS (ttm)	-1.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	160,821
Open	1.560
Previous Close	1.570
Day's Range	1.490 - 1.600
52-Week Range	1.470 - 5.120
Beta	2.01
Analysts	Strong Buy
Price Target	9.50 (+533.33%)
Earnings Date	Apr 8, 2024

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 2, 2018
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: CUE

Financial Performance

In 2023, Cue Biopharma's revenue was $5.49 million, an increase of 340.96% compared to the previous year's $1.25 million. Losses were -$50.73 million, -4.30% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for CUE stock is "Strong Buy." The 12-month stock price forecast is $9.5, which is an increase of 533.33% from the latest price.

Price Target

$9.5

(533.33% upside)

Analyst Consensus: Strong Buy